Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 129,600 shares of the company’s common stock with a per share exercise price of $24.12, the closing trading price on the grant date, and 64,800 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
